# Huadong Medicine

Huadong Medicine is a Corporate Investor based in Hangzhou, China.

## Overview

- **Organization type:** Corporate Investor
- **Headquarters:** Hangzhou, China
- **Region:** Asia
- **Address:** No. 866 Moganshan Road, Gongshu District, Hangzhou, Zhejiang, China
- **Founded:** 1993
- **Assets under management:** Undisclosed
- **Website:** eastchinapharm.com
- **LinkedIn:** https://www.linkedin.com/company/huadong-medicine

## Regulatory record

- **Reports private funds:** No

## About

Huadong Medicine was founded in 1993 by Hu Kaijun, who controls the company through its parent investment group, China Grand Enterprises. The Hangzhou-based operation began as a pharmaceutical distributor before integrating backward into manufacturing and forward into specialty drug R&D, crafting a vertically integrated model that is unusual among China's listed pharma companies. The firm's strategy rests on a three-pillar structure: specialty generic manufacturing, commercial distribution at scale, and a growing pipeline of innovative biologics in-licensed from global partners. Its manufacturing base produces immunosuppressants, diabetes drugs, and oncology treatments, while its distribution network covers over 30,000 medical institutions. In recent years, Huadong has expanded into aesthetic medicine, acquiring distribution rights for Korean botulinum toxin products and building a medical aesthetics subsidiary. The firm also operates industrial parks in Zhejiang, including the Huadong Medicine Life Science Industrial Park, which serves as a manufacturing and R&D hub. Huadong Medicine employs thousands across its manufacturing bases and distribution centers in Hangzhou, Jinhua, and Wenzhou. Its parent, China Grand Enterprises, provides a holding-company structure that separates operating assets from other family holdings. The firm also supports the Flower of Life Family Living Organ Transplantation Charitable Fund, a philanthropic vehicle tied to its origins in transplant medicine. In 2023, the company reported revenue of approximately $5.5B, marking steady growth from its base generics business. What distinguishes Huadong from other Chinese pharma firms is its dual identity as both an operating company and a strategic investor. Rather than deploying third-party capital, it reinvests operating cash flow directly into adjacent verticals — most recently building an aesthetic medicine franchise alongside its traditional drug business. This structure concentrates investment authority with Lv Liang and ultimate controller Hu Kaijun, creating a decision-making architecture that can move capital across the pharma value chain without the friction of external LP approvals.

## Sectors

- Pharmaceuticals
- Healthcare Services
- Biotechnology

## People

- Lv Liang — Chairman and CEO
- Hu Kaijun — Ultimate Controller (via China Grand Enterprises)

## Questions

### How is Huadong Medicine structured relative to its parent, China Grand Enterprises?

China Grand Enterprises serves as the holding company through which founder Hu Kaijun controls Huadong Medicine. The structure separates the listed operating company from other family assets, with Huadong Medicine operating as a publicly traded entity that handles the core pharmaceutical business — manufacturing, distribution, and R&D — while the parent provides strategic oversight.

### What role does medical aesthetics play in Huadong Medicine's current strategy?

Medical aesthetics has become a significant growth vertical for Huadong, complementing its traditional generic drug business. The firm has in-licensed Korean botulinum toxin products, built a subsidiary dedicated to aesthetic medicine, and secured NMPA approval for injectable fillers through its Sinclair Pharma unit, positioning itself to capture demand from China's expanding medical aesthetics market.

### How does Huadong Medicine's logistics infrastructure support its investment strategy?

The firm owns distribution hubs in Hangzhou, Jinhua, and Wenzhou that form the backbone of a commercial network reaching over 30,000 medical institutions. These logistics assets reduce dependence on third-party distributors and create a platform advantage when in-licensing new products — Huadong can guarantee distribution reach that pure financial investors cannot match.

### Who runs investment decisions at Huadong Medicine?

Chairman and CEO Lv Liang holds operational authority over investment and capital allocation decisions, subject to oversight from the parent company controlled by Hu Kaijun. The firm does not operate an independent investment committee structure typical of family offices, instead routing strategic decisions through its corporate governance framework as a publicly listed entity.

## Related profiles

- [Huachuang Securities](https://altss.com/profile/huachuang-securities)
- [Huafang Group](https://altss.com/profile/huafang-group)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/huadong-medicine

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology